AbbVie (ABBV) Free Cash Flow (2012 - 2026)

AbbVie has disclosed Free Cash Flow across 15 years of filings, most recently posting $3.6 billion for Q1 2026.

• In Q1 2026, Free Cash Flow rose 154.57% year-over-year to $3.6 billion; the TTM figure through Mar 2026 stood at $20.0 billion (up 29.87% YoY), while the FY2025 annual figure was $17.8 billion, changed 0.09% from the prior year.
• Free Cash Flow fell to $3.6 billion in Q1 2026, from $4.9 billion in the prior quarter.
• Over the last five years, Free Cash Flow for ABBV reached as high as $7.4 billion in Q3 2022 and fell as low as $1.4 billion in Q1 2025.
• The 5-year median for Free Cash Flow is $4.9 billion (2025), against an average of $5.0 billion.
• Annual changes were most pronounced in 2024 — Free Cash Flow plunged 66.94% — and 2026, when it soared 154.57%.
• A 5-year view of Free Cash Flow shows it stood at $7.2 billion in 2022, then slumped by 36.96% to $4.5 billion in 2023, then soared by 48.57% to $6.8 billion in 2024, then slipped by 27.65% to $4.9 billion in 2025, then slipped by 27.1% to $3.6 billion in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered $3.6 billion, $4.9 billion, and $6.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.